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mutations as a cause of autosomal recessive
nonsyndromic hearing loss in Korean families
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and Soo Kyung Koo1*Abstract
Background: The genetic heterogeneity of hearing loss makes genetic diagnosis expensive and time consuming
using available methods. Whole-exome sequencing has recently been introduced as an alternative approach to
identifying causative mutations in Mendelian disorders.
Methods: To identify the hidden mutations that cause autosomal recessive nonsyndromic hearing loss (ARNSHL),
we performed whole-exome sequencing of 13 unrelated Korean small families with ARNSHL who were negative for
GJB2 or SLC26A4 mutations.
Results: We found two novel compound heterozygous mutations, IVS11 + 1 and p.R2146Q, of MYO15A in one
(SR903 family) of the 13 families with ARNSHL. In addition to these causative mutations, 13 nonsynonymous
variants, including variants with uncertain pathogenicity (SR285 family), were identified in the coding exons of
MYO15A from Korean exomes.
Conclusion: This is the first report of MYO15A mutations in an East Asian population. We suggest that close
attention should be paid to this gene when performing genetic testing of patients with hearing loss in East Asia.
The present results also indicate that whole-exome sequencing is a valuable method for comprehensive medical
diagnosis of a genetically heterogeneous recessive disease, especially in small-sized families.
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Hearing loss is one of the most common sensory disorders
and a heterogeneous trait in human beings [1]. More than
50% of prelingual deafness is estimated to have a genetic
etiology, of which about 70% is nonsyndromic hearing
loss (NSHL). Eighty percent of NSHL is autosomal re-
cessive nonsyndromic hearing loss (ARNSHL). To date,
more than 100 mapped loci have been reported, and 55
nonsyndromic hearing loss genes have been identified
(http://hereditaryhearingloss.org/).
The genes that are most commonly implicated in
ARNSHL are in order of frequency: GJB2, SLC26A4,* Correspondence: skkoo@nih.go.kr
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reproduction in any medium, provided the orMYO15A, OTOF, and CDH23 [2]. Mutations in these
genes do not occur at the same frequencies across eth-
nicities. Thus, the current genetic diagnosis of hearing
loss is limited to common mutations in a patient’s popu-
lation of origin and relies on a gene-specific Sanger se-
quencing approach. This method is useful in some
populations. For example, in Caucasians, mutation of a
single gene, GJB2, accounts for up to 50% of all cases of
ARNSHL [3]. However, in East Asian populations, GJB2
is responsible for a much lower percentage of deafness
cases, and other genes associated with this disease re-
main largely unknown [4].
Mutations in MYO15A are among the most frequent
causes of ARNSHL worldwide [2]. Forty-three mutations
have been reported in MYO15A, most of which have
been found by linkage analysis in consanguineous fam-
ilies from specific countries, such as Pakistan, Turkey,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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routinely offered owing to its large size, and the fre-
quency and spectrum of MYO15A mutations in most
ethnic populations are not known.
Recent advances in DNA enrichment and next-generation
sequencing (NSG) technology have allowed rapid and
cost-effective analysis of the causative mutations for hu-
man disorders [8]. Several studies have demonstrated the
sensitivity and accuracy of the exome sequencing approach
as well as the clinical utility of whole-exome sequencing
[9,10]. In the present study, we applied whole-exome
sequencing to 16 individuals from 13 unrelated families




All affected individuals had bilateral and severe to pro-
found hearing loss without additional symptoms, and
had been diagnosed with hearing impairment at an early
age. Informed consent was obtained from all partici-
pants, and this study was approved by the Institutional
Review Board of the Korea National Institutes of Health
(NIH). Genomic DNA was extracted from peripheral
blood samples using a FlexiGene DNA extraction kit
(QIAGEN, Hilden, Germany). Probands from each fam-
ily were found to be negative for GJB2 and SLC26A4
mutations based on Sanger sequencing.
Whole-exome sequencing
Five micrograms of DNA were captured on the SeqCap EZ
Human Exome Library v2.0 (Roche/NimbleGen, Madison,
WI), following the manufacturer’s protocol. We targeted
all well-annotated protein-coding regions as defined by
the CCDS (September 2009). Captured libraries were se-
quenced on the Solexa GAIIx Genome Analyzer (Illumina,
San Diego, CA) with 78-bp paired-end reads, following
the manufacturer’s protocol. Reads were mapped to the
reference human genome (GRCh37, UCSC hg19) using
BWA (http://bio-bwa.sourceforge.net/). Single-nucleotide
variants (SNVs) and insertions-deletions (indels) were
identified using the SAMtools (http://samtools.sourceforge.
net/), based on filtered variants with a mapping quality
score ≥20, and annotated using ANNOVAR (http://www.
openbioinformatics.org/annovar/). Mutations identified by
exome sequencing were confirmed by Sanger sequencing
and genotyped with additional control individuals using
TaqMan SNP Genotyping Assays (Applied Biosystems,
Foster City, CA). Exome-based copy-number variation
(CNV) was analyzed using the ExomeCNV programs [11].
Sanger sequencing
PCR and direct sequencing were used to prescreen
GJB2 and SLC26A4 and to confirm the variants in thecandidate genes that had been identified by exome
sequencing. We also applied direct sequencing to read
the missing regions (read depth <5) of candidate genes
that were identified using Tablet – Next Generation
Sequence Assembly Visualization [12]. The PCR prod-
ucts were directly sequenced, in both the forward
and reverse directions, using an ABI 3730 instrument
(Applied Biosystems). Each read was aligned to the ref-
erence sequence, and nucleotide changes were identi-
fied with the Sequencer software package (GeneCodes,
Ann Arbor, MI).
In silico analysis
Evolutionary conservation of the sequences and struc-
tures of the proteins and nucleic acids was assessed
using the ConSeq server (http://conseq.tau.ac.il/). The
effect of the identified novel missense mutation was
assessed using SIFT (http://sift.jcvi.org), PolyPhen-2
(http://genetics.bwh.harvard.edu/pph2/index.shtml), and
MUpro (http://mupro.proteomics.ics.uci.edu/). These are
automatic tools for predicting the impact of an amino
acid substitution on the structure and function of a hu-
man protein. The 3D molecular structure of the MyTH4
domain was modeled using SWISS-MODEL Workplace
(http://swissmodel.expasy.org/). The images were cap-




We performed whole-exome sequencing of 16 individuals
from 13 unrelated families with ARNSHL, and found
compound heterozygous mutations in the MYO15A gene
from the SR-903 family, as well as a novel variant in
the same gene from the SR-285 family (Additional file 1:
Figure S1).
A summary of the exome sequencing results for the
two families is provided in Table 1. On average, 97% and
90% of the bases were covered to 1× and 10× within the
targeted bases, respectively. The average number of ob-
served variants was 55,828. To identify pathogenic vari-
ants, we filtered out polymorphisms using the Single
Nucleotide Polymorphism Database dbSNP131 and the
Korean exome data, which includes exome data for 30
Koreans from another study [13], and the Korean gen-
ome database, TIARA [14]. We then focused on the var-
iants of reported nonsyndromic deafness genes.
Identification of causative mutations
In samples SR-903 and SR-903B, the numbers of
remaining variants were five and three, respectively
(Table 1, Additional file 2: Table S1). Of these, three var-
iants in MYO15A (IVS11 + 1, p.R2146Q, and p.S3474G)
were shared by both siblings. The p.S3474G variant was
Table 1 Results of whole-exome sequencing of three individuals with ARNSHL
Parameter SR-903 SR-903B SR-285
Total reads 66,179,458 74,672,946 65,182,498
Total yield (bp) 5,161,997,724 5,824,489,788 5,084,234,844
Mappable reads 61,470,184 68,485,482 60,376,538
Mappable yield (bp) 4,669,705,365 5,194,083,022 4,596,079,334
On-target reads 39,914,806 41,803,453 36,505,698
On-target yield (bp) 2,458,150,580 2,594,965,223 2,203,746,888
Coverage of target region (more than 10×) 91% 89% 91%
Mean read depth of targeted region 56× 59× 50×
Mean read depth of called variants 46× 50× 42×
Number of total variants 56,505 54,340 56,640
Number of coding variants 20,849 20,597 20,847
Number of missense, nonsense, splice, and indel variants 10,633 10,425 10,574
After Korean control exome* filtering 543 548 510
After dbSNP131 filtering 457 472 447
Variants in reported deafness genes 5 3 3
Shared variants 3 3 -
* Korean control exome dataset, which includes exome data for 30 Koreans from another study and the Korean genomes database, TIARA.
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database with a minor allele frequency (MAF) of 0.002,
and it also appeared in dbSNP137(rs150181830). Sanger
sequencing confirmed the other two variants in the af-
fected siblings and their family. One variant, correspond-
ing to p.R2140Q, was heterozygotic in the patient’s
father (SR-903 F). The other variant, IVS11 + 1G > A,
was present in the mother (SR-903 M) (Figure 1).
SR-285 carried three candidate variants of known deaf-
ness genes (p.Q445R in GRHL2, p.T1321S in TECTA,
and p.S2161F in MYO15A); only one mutation, p.S2161F
inMYO15A, was shared with an affected sibling (Figure 1).
However, it was found to be in a heterozygous state
without a second mutation. To search for other muta-
tions, we subsequently sequenced the entire missing
region (read depth <5) in all 66 exons of MYO15A
(NM_016239). However, no additional mutation or small
insertion or deletion was identified. In addition, no signifi-
cantly suggestive copy-number variation (CNV) region
emerged from the exome-based CNV analysis. SR-285
was found to contain another MYO15A coding variant,
p.G1220R, which was also shared by both affected sibling
but was filtered out in the initial analysis due to its appear-
ance in the Korean exome data (Additional file 2: Table
S2). In the present study, we regard this variant as a
polymorphism, although given the recessive nature of
this gene, it is feasible that a low frequency in the general
Korean population could render it pathogenic. Unfortu-
nately, DNA samples were not available from the parentsin this family and we could not confirm pathogenicity in a
segregation study.
In silico analysis of mutations detected in MYO15A
Compound heterozygous mutations in MYO15A, IVS11 +
1 and p.R2146Q, were found in the SR-903 family,
while a heterozygous variant, p.S2161F was identified
in the SR-285 family. All of the probable causative mu-
tations were novel and were not present in 409 ethnic-
ally matched controls (Table 2). The ConSeq server
revealed that all of the causative mutations were lo-
cated at a well-conserved site. Residues R2146 and
S2161 are both located in the first MyTH4 domain of
the MYO15A protein (Figure 2A). Figure 2B presents
the locations of R2146 and S2161 in a 3D model of the
MyTH4 domain based on PBD entry 3pvlA. In the first
variant, the substitution of an uncharged, polar glutam-
ine for arginine results in the loss of the positive charge
on the arginine side-chain (p.R2146Q). In the other
variant, the polar side chain of serine is replaced with a
non-polar phenylalanine side-chain (p.S2161F). Both al-
terations are predicted by SIFT to be deleterious. The
IVS11 + 1G > A alteration is predicted to affect splicing,
thereby prematurely terminates.
Identification of MYO15A polymorphism
In addition to these causative mutations, 12 nonsynonymous
variants were identified in the MYO15A coding exons
from 17 hearing-loss patients and 30 Korean control
Figure 1 Confirmation of novel pathogenic variants in MYO15A. Causative mutations were confirmed by capillary sequencing of DNA from
the families of affected patients. (A) In family SR-903, compound heterozygous mutations, IVS11 + 1G > A and p.R2146Q, are carried by both
affected siblings, SR-903 and SR-903B. The heterozygous IVS11 + 1G > A mutation is from the mother (SR-903 M), and the other heterozygous
p.R2146Q mutation is from the father (SR-903 F). (B) SR-285 carries the heterozygous p.S2161F mutation in MYO15A, and this mutation was
confirmed in the affected sibling SR-285S. All the pathogenic variants occur at a highly conserved position. The corresponding DNA sequences
appear in red.
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variants to be polymorphisms because they did not
cosegregate with an affected member or were found in
the controls.
Discussion
We performed whole-exome sequencing and identified
novelMYO15Amutations in Korean families with ARNSHL.
Comprehensive targeted enrichment and massive paral-
lel sequencing have been employed for nonsyndromic
hearing loss [15-17] and have focused only on the
exons of all known deafness genes. However, the cost









SR-903 Chr17:18035881 c.4320 + 1G IVS11 + 1 Intron
SR-903 Chr17:18049349 c.G6437A p.R2146Q Exon 29 M
Variants with uncertain pathogenicity
SR-285 Chr17:18049394 c.C6482T p.S2161F Exon 29 M
1 For SIFT, prediction of a change being deleterious (<0.05) or tolerated.
2 For PolyPhen-2, prediction of a change being deleterious (>0.85), possibly deleter
3 For MUpro, prediction of a change that decreases protein stability (score <0) or in
The English in this document has been checked by at least two professional editors
http://www.textcheck.com/certificate/GVv7E3.for only the deafness genes alone, and novel genes for
hearing loss have been identified by a targeted NGS ap-
proach [18,19]. Thus, we targeted the whole exome to
identify causative mutations in known deafness genes,
as well as novel mutations responsible for hearing loss.
To identify pathogenic variants, we filtered out poly-
morphisms using the dbSNP131 and the Korean exome
data. As an example, 1,462 variants in SR-903 remained
after the dbSNP131 filtering. In contrast, after Korean
exome filtering, 543 variants remained. This means that
some variants that are commonly found in the Korean
population are not present in dbSNP131. The applica-





Motor 0/409 Yes - - -
yTH4 0/409 Yes 0 0.99 −0.743
yTH4 0/409 Yes 0 1 −0.543
ious (0.15–0.85) or benign (<0.15).
creases protein stability (score >0), with a confidence score between −1 and 1.
, both native speakers of English. For a certificate, please see:
Figure 2 MYO15A gene structure and a 3D model of the MyTH4 domain. (A) The novel MYO15A mutations reported in this study are
indicated at the top of the figure, and previously reported mutations are listed at the bottom of the figure. (B) The MyTH4 domain comprises an
alpha-helix (red) and loops (green). The locations of R2146 and S2161 are shown in magenta and cyan, respectively.
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deafness genes also greatly reduced the number of can-
didate variants (Table 1). In sibling samples, the identifi-
cation of causative mutations is straightforward, as the
mutation must be present in both siblings.
MYO15A (66 coding exons) encodes an unconven-
tional myosin (myosin XVA; 3,530 amino acids) that is
expressed in the cochlea [20]. This protein has import-
ant roles in the differentiation and elongation of the
inner ear hair cell stereocilia [21], and it is necessary
for actin organization in hair cells [22]. Mutations that
cause hearing loss were first identified at the DFNB3
locus, in residents of a village in Indonesia. Since then,
many mutations have been reported from Pakistan,
India, Turkey, Indonesia, and Brazil [5,7]. However,
the two mutations identified in the present study are
novel and are the first MYO15A mutations reported in
East Asians.
IVS11 + 1 is located in the motor domain of myosin
XVA. The motor domain contains ATP- and actin-
binding sites and produces the force that moves actinfilaments in vitro [23]. Homozygous Shaker-2 (sh2)
mice are deficient in myosin XVA due to a premature
stop codon in the motor domain of the protein [24].
These mice exhibit profound deafness, similar to that
observed in human DFNB3 patients. There are many
reported mutations in this domain, and we propose
that these mutations probably have deleterious effects
on protein function.
Two missense mutations, p.S2161F and p.R2146Q,
are located in exon 29, the first MyTH4 domain. The
MyTH4 domain of myosin has been implicated in
microtubule binding, as well as in actin binding at the
plasma membrane [25]. There are data to suggest that
the MyTH4/FERM domain in myosin VIIA is required
for its localization to stereocilia tips [25-27], a process
that is essential for the formation of the transmem-
brane actin microfilament assembly complex at the
stereocilia tips. A recent study revealed that many
deafness-causing mutations occur in this domain, and
provided mechanistic explanations for known deafness-
causing mutations in MYO7A MyTH4-FERM using
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myosin XVA, it has been reported that p.R2124Q and
p.P2073S mutations located in the MyTH4 domain
interfere with the interaction between myosin XVA and
whirlin so as to prevent the formation of a complex
that appears to be required for normal hearing [28]. In
the present study, we identified two novel mutations,
p.S2161F and p.R2146Q, which are located in the
MyTH4 domain. These mutations may result in patho-
genesis and deafness and may have important roles in
the functions of myosin XVA. The p.R2146Q protein
contains a prominent exposed hydrophobic pocket with
positively charged residues and has a structure that is
similar to the reported R1190 of MYO7A MyTH4-
FERM. This region may directly bind to CEN2 at the
negatively charged residues, and substitution with un-
charged residues leads to an approximately 10-fold de-
crease in the binding affinity between MFS and CEN
[27]. Therefore, we speculate that the p.R2146Q muta-
tion cripples the inter-MyTH4-FERM interface that
could lead to pathogenesis and deafness.
In SR-285, we identified two novel nonsynomous vari-
ants, p.G1220R and p.S2161F, in the MYO15A gene.
Both of these variants were shared with the affected sib-
ling. However, as the heterozygous variant p.G1220R
was present in the Korean control exome data, we re-
gard it as a polymorphism. Consequently, we could not
identify a second deleterious mutation in this family.
However, another variant, p.S2161F, was absent in 409
ethnically matched controls and was predicted to have a
pathogenic effect on protein structure or function by in
silico analysis; we would not rule out the possibility of a
causative MYO15A gene mutation in this family. There
are two possible explanations for the hearing loss ob-
served in this family: (1) p.G1220R contributes to the
phenotype of the SR-285 family and has a low frequency
in the general Korean population; and (2) a pathogenic
mutation exists in the MYO15A gene but in an exon
that was not covered by our sequencing or it lies within
intronic regulatory sequences. This problem highlights
a limitation of exome-based analyses. Alternatively, a
pathogenic mutation exists in another known gene
uncovered by WES or the causative mutation is in
an as-yet-unidentified hearing loss gene. Even though
p.S2161F was not the causative mutation in this family,
it has the potential to exert pathogenic effects on protein
function in other families with hearing loss, as supported
by the in silico analysis. Further functional assays to
prove the pathogenicity of this variant would be useful
to confirm the deleterious nature of this variant.
The GJB2 and SLC26A4 genes are frequently impli-
cated in ARNSHL, and screening for these genes is rela-
tively easy. Therefore, many studies have focused on
only these two genes. However, a strategy for screeningother hearing loss genes is difficult, and Sanger sequen-
cing of candidate genes with multiple exons, such as
MYO15A, is time-consuming. To screen simultaneously
for each of the known deafness genes and to discover
hidden mutations, we initially performed WES on 16
individuals from 13 unrelated smaller families with
ARNSHL who could not be analyzed using the current
genetic approach owing to insufficient genetic informa-
tion following the exclusion of mutations in the GJB2
and SLC26A4 genes using Sanger sequencing. We identi-
fied a compound heterozygous mutation in MYO15A in
one family and a novel variant in the same gene from
another family. To our knowledge, this is the first report
of MYO15A mutations in an East Asian population. It
seems likely that there are additional ARNSHL-causing
MYO15A mutations, as the gene is large and mutation
analysis is rare, since complementary linkage analysis
has not been performed in East Asian populations. The
exact frequency of such mutations will need to be deter-
mined in a future larger cohort mutation analysis and
close attention should be paid to this gene when
performing genetic testing of patients with hearing loss
in East Asia.Conclusions
In summary, we identified mutations in the MYO15A
gene in a East Asian population for the first time using
whole-exome sequencing. The present results indicate
that whole-exome sequencing is a valuable method for
comprehensive medical diagnosis and provides a valu-
able alternative to analyzing all known causative genes
by conventional sequencing in a genetically heteroge-
neous disease, especially in small-sized families. In the
future, the rapid discovery of hearing loss-related genes
by whole-exome sequencing is expected and will provide
a better understanding of the condition.Additional files
Additional file 1: Figure S1. Pedigrees of two families with autosomal
recessive nonsyndromic hearing loss. (A) Family SR-903 carries a
compound heterozygous mutation in MYO15A, which is shared by both
siblings. (B) In family SR-285, only one mutation, p.S2161F in MYO15A, is
shared with the affected sibling. Filled symbols in each pedigree
represent affected individuals. The proband is indicated by an arrow.
Asterisks indicate available samples. The three individuals whose exomes
were sequenced are shown in red.
Additional file 2: Table S1. Candidate variants identified in this study.
Table S2. Nonsynonymous mutations considered to be noncausative
variations in 16 hearing-loss patients and 30 Korean exomes from
another study.Abbreviations
NSHL: Nonsyndromic hearing loss; ARNSHL: Autosomal recessive
nonsyndromic hearing loss; NGS: Next generation sequencing.
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